The following Press Release was issued by AdvaMed on 40 most Innovative companies presentations on September 27th 2007 Pradeep M Gupte, CEO of Rockland Technimed Ltd, presented Oxy-17® (26)
Dr. Robert L. DeLaPaz for the Expert Panel on Neurologic Imaging: American College of Radiology : Appropriateness Criteria for Cerebrovascular Disease AJNR Jun-Jul 2007 (25)
Nukem GmbH issued the follwing Press Release as an exhibitor at the Society of Nuclear Medicine Annual meeting In Washington DC in June 2007 (24)
Rockland Technimed Ltd announced the Human Stroke imaging demos with Oxy-17 beginning May 14th in India (23)
Rockland Technimed Ltd and Nukem GmbH host a dinner symposium of leading scientists May 22, 2007 at the International Club -Berlin (22)
Rockland Technimed Ltd and Nukem exhibit Oxy-17(R) products at the Berlin Meeting May 2007 (21)
Rockland Technimed Ltd enters into Indian Market (20)
NUKEM GmbH, and Rockland Technimed Ltd have entered into a contract (19)
Availibility of Oxy-17® product for research investigations only in the USA (18)
RTL at IBC's 11th Annual World Congress meeting in Boston August 2006 (17)
"Memorandum of Understanding Regarding the Cooperation in the field of the Isotope Oxygen-17" was executed between RWE NUKEM GmbH, and Rockland Technimed Ltd (16)
RTL announced today, that a formal IND/NDA submission has been filed with the US Food and Drug Administration for its patented product Oxy-17tm (15)
RTL announced that an application has been filed with the US Food and Drug Administration for its patented product Oxy-17tm (14)
Appointment of Dr John Pile-Spellman as Vice President of Research- (13)
Appointment of Dr Robert DeLaPaz (12)
Appointment of Mr Elliot Cole- (11)
Robert L. DeLaPaz,, MD, presented the results of his teams work with RTL's Tissue Viability Imaging contrast media -10
CIBC World Markets 13th Healthcare Conference-9
NEW YORK PRESBYTERIAN HOSPITALS of Columbia and Cornell university and ROCKLAND TECHNIMED LTD signed a "Letter of Intent"-8
Pradeep M Gupte was invited to present Rockland Technimed Ltd's Tissue Viability Imaging technology-7
ALLEGHENY GENERAL HOSPITAL AND RTLSCIENTISTS PRESENT RESULTS WITH THE TVI-GENT FOR DETECTION OF VIABILITY IN MYOCARDIAL INFARCTION (PRECLINICAL STUDIES)-6
RTL SCIENTISTS TO PRESENT PRELIMINARY RESULTS WITH THE TVI-GENT FOR TISSUE VIABILITY ASSESSMENT USING PROTON MRI (PRECLINICAL STUDIES)-5
RTL RECEIVES PATENT APROVAL IN JAPAN FOR ITS " TISSUE VIABILITY IMAGING " TECHNOLOGY-4
RTL ANNOUNCES A LICENSING AGREEMENT FOR THE DEVELOPMENT OF TISSUE VIABILITY IMAGING AGENT FOR MRI WITH VIVO RX PHAMACEUTICAL INC, SANTA MONICA, CA.-3



Album of photographs at the Dinner Sympoium on the "Use of Oxygen-17" by leading world scientists in conjunction with the joint annual meeting of ESMRMB and ISMRM Berlin May 22nd 2007- International Club-Berlin. Hosted jointly by Rockland Technimed Ltd and Nukem GmbH. (click on the link here)


What the press says :

Rockland Technimed Ltd.
Maratha House, 3 Larissa Court, Airmont, NY USA
Telephone: 001-(845)-426-3406, Fax -001- (845)-426-1109
Email - info@technimed.com Webmaster - webmaster@technimed.com
Copyright © 1999-2007 Rockland Technimed Ltd. All rights reserved.
Oxy-17® is a registered Trade Mark of Rockland Technimed Ltd for: Oxygen-based diagnostic agents, preparations and substances for medical purposes, namely, contrast media for medical imaging for use with MRI diagnostic apparatus, and diagnostic scanning agents in the nature of contrast media for use in In-Vivo imaging.